HER-2/ neu Oncogene Amplification and Expression in Human Mammary Carcinoma

[1]  I. Ellis,et al.  c-erbB-2 oncoprotein expression in primary and advanced breast cancer. , 1991, British Journal of Cancer.

[2]  A. Harris,et al.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. , 1991, British Journal of Cancer.

[3]  R. Lupu,et al.  Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. , 1990, Science.

[4]  S. Naber,et al.  Strategies for the analysis of oncogene overexpression. Studies of the neu oncogene in breast carcinoma. , 1990, American journal of clinical pathology.

[5]  W. McGuire,et al.  HER-2/neu amplification predicts poor survival in node-positive breast cancer. , 1990, Cancer research.

[6]  J. Bacus,et al.  HER-2/neu oncogene expression and proliferation in breast cancers. , 1990, The American journal of pathology.

[7]  G M Clark,et al.  How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.

[8]  J. Pierce,et al.  Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene , 1990, Molecular and cellular biology.

[9]  S. Hirohashi,et al.  correlation between histologic grade of malignancy and copy number of c‐erbb‐2 gene in breast carcinoma. A retrospective analysis of 176 cases , 1990, Cancer.

[10]  K. Leslie,et al.  Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma. , 1990, Archives of pathology & laboratory medicine.

[11]  W. Franklin,et al.  In situ distribution of oncogene products and growth factor receptors in breast carcinoma: c-erbB-2 oncoprotein, EGFr, and PDGFr-beta-subunit. , 1990, Molecular and cellular probes.

[12]  T. Pawson,et al.  Distribution and patterns of staining of Neu oncogene product in benign and malignant breast diseases. , 1990, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[13]  W. Gullick,et al.  c‐erbB‐2 oncoprotein expression in primary human tumors , 1990, Cancer.

[14]  C R King,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  G. Hortobagyi,et al.  c-erbB-2 amplification in node-negative human breast cancer. , 1989, Cancer research.

[16]  S. Skates,et al.  Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. , 1989, Cancer research.

[17]  H. Roels,et al.  The subcellular localization of the neu protein in human normal and neoplastic cells , 1989, International journal of cancer.

[18]  S. Mori,et al.  Association of Elevated Expression of the c‐erbB‐2 Protein with Spread of Breast Cancer , 1989, Japanese journal of cancer research : Gann.

[19]  M. Aapro,et al.  Genetic alterations of c-myc, c-erbB-2, and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. , 1989, Cancer research.

[20]  Y. Shiloh,et al.  Amplification of c‐myc and c‐erbB‐2 proto‐oncogenes in human solid tumors: Frequency and clinical significance , 1989, International journal of cancer.

[21]  C. Benz,et al.  Expression of c-myc, c-Ha-ras1, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. , 1989, Journal of the National Cancer Institute.

[22]  C. Theillet,et al.  Proto-oncogene amplification and human breast tumor phenotype. , 1989, Oncogene.

[23]  M. Vijver,et al.  The expression of the neu oncogene product in breast lesions and in normal fetal and adult human tissues , 1989, Histopathology.

[24]  P. Quirke,et al.  c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma. , 1989, British Journal of Cancer.

[25]  J. Varley,et al.  An evaluation of immunoreactivity for c-erbB-2 protein as a marker of poor short-term prognosis in breast cancer. , 1989, British Journal of Cancer.

[26]  W. McGuire,et al.  HER-2/neu oncogene protein and prognosis in breast cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  T. Akiyama,et al.  C-erbB-2 gene product, a membrane protein commonly expressed on human fetal epithelial cells. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[28]  P. Quirke,et al.  Pattern of expression of c-erbB-2 oncoprotein in human fetuses. , 1989, British Journal of Cancer.

[29]  P. Jolicoeur,et al.  Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene , 1989, Cell.

[30]  S. Hirohashi,et al.  Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. , 1989, Cancer research.

[31]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[32]  B Angus,et al.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. , 1989, Cancer research.

[33]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[34]  C K Osborne,et al.  Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. An intergroup study. , 1989, The New England journal of medicine.

[35]  C. Redmond,et al.  A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.

[36]  C. Redmond,et al.  A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.

[37]  W. McGuire.  Adjuvant therapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[38]  M. Kraus,et al.  Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. , 1989, Oncogene.

[39]  R. Zeillinger,et al.  HER-2 amplification, steroid receptors and epidermal growth factor receptor in primary breast cancer. , 1989, Oncogene.

[40]  M. Cline,et al.  Proto-oncogene abnormalities in human breast cancer: c-ERBB-2 amplification does not correlate with recurrence of disease. , 1989, Oncogene.

[41]  T. Powles,et al.  Immunohistochemical distribution of c‐erbB‐2 in infiltrating and in situ breast cancer , 1988, International journal of cancer.

[42]  M. J. van de Vijver,et al.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. , 1988, The New England journal of medicine.

[43]  B. Gusterson,et al.  c-erbB-2 expression in benign and malignant breast disease. , 1988, British Journal of Cancer.

[44]  D. Altman,et al.  An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. , 1988, British Journal of Cancer.

[45]  Cori Bargmann,et al.  Oncogenic activation of the neu‐encoded receptor protein by point mutation and deletion. , 1988, The EMBO journal.

[46]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[47]  G. Clark,et al.  Amplification of c-erbB-2 and aggressive human breast tumors? , 1988, Science.

[48]  Y. Shiloh,et al.  Sporadic amplification of the HER2/neu protooncogene in adenocarcinomas of various tissues. , 1988, Cancer research.

[49]  B. Groner,et al.  Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. , 1988, Cancer research.

[50]  J. Yokota,et al.  Association of multiple copies of the c-erbB-2 oncogene with spread of breast cancer. , 1987, Cancer research.

[51]  W. Gullick,et al.  OVEREXPRESSION OF THE c-erbB-2 ONCOPROTEIN IN HUMAN BREAST CARCINOMAS: IMMUNOHISTOLOGICAL ASSESSMENT CORRELATES WITH GENE AMPLIFICATION , 1987, The Lancet.

[52]  C R King,et al.  erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. , 1987, Science.

[53]  J. Yokota,et al.  Proto-oncogene abnormalities in human breast cancer: correlations with anatomic features and clinical course of disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[55]  W. J. Brammar,et al.  Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. , 1987, Oncogene.

[56]  R. Weinberg,et al.  Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[57]  J. Yokota,et al.  AMPLIFICATION OF c-erbB-2 ONCOGENE IN HUMAN ADENOCARCINOMAS IN VIVO , 1986, The Lancet.

[58]  P. Seeburg,et al.  Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. , 1985, Science.

[59]  K. Semba,et al.  A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Weinberg,et al.  The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor. , 1985, Science.

[61]  C R King,et al.  Amplification of a novel v-erbB-related gene in a human mammary carcinoma. , 1985, Science.

[62]  Robert A. Weinberg,et al.  Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies , 1985, Cell.

[63]  R. Weinberg,et al.  The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen , 1984, Nature.

[64]  R. Weinberg,et al.  Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas , 1982, Cell.

[65]  R. Weinberg,et al.  Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts , 1981, Nature.

[66]  H. Third.  Hæmolytic Disease of the New-Born , 1958, Nature.